<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the tremendous efforts invested in 
 <italic>Flavivirus</italic> research, no clinically approved antiviral chemotherapeutics are available for humans, and disease treatment is limited to supportive care [
 <xref rid="pone.0223017.ref013" ref-type="bibr">13</xref>]. Inhibition of viral enzymes has proved to be one important approach toward the development of antiviral therapies [
 <xref rid="pone.0223017.ref002" ref-type="bibr">2</xref>, 
 <xref rid="pone.0223017.ref013" ref-type="bibr">13</xref>â€“
 <xref rid="pone.0223017.ref015" ref-type="bibr">15</xref>]. Non-structural proteins encoded by these RNA viruses are essential for their replication and maturation, and thus may offer ideal targets for developing antiviral drugs [
 <xref rid="pone.0223017.ref002" ref-type="bibr">2</xref>]. 
 <italic>Flavivirus</italic> genomes are translated into a single polyprotein that needs to be cleaved by viral and host proteases. Because it processes most of the polyprotein cleavages, viral protease is necessary and essential for virus replication [
 <xref rid="pone.0223017.ref016" ref-type="bibr">16</xref>, 
 <xref rid="pone.0223017.ref017" ref-type="bibr">17</xref>].
</p>
